300255 常山药业
已收盘 10-29 15:00:00
资讯
新帖
简况
图解常山药业三季报:第三季度单季净利润同比下降34.36%
证券之星 · 32分钟前
图解常山药业三季报:第三季度单季净利润同比下降34.36%
常山药业(300255.SZ)发布前三季度业绩,归母净亏损3789.44万元
智通财经 · 17:56
常山药业(300255.SZ)发布前三季度业绩,归母净亏损3789.44万元
常山药业:公司已按要求提交补充资料
证券之星 · 10-21
常山药业:公司已按要求提交补充资料
常山药业:截至2026年10月20日,公司的股东户数为60539户
证券之星 · 10-21
常山药业:截至2026年10月20日,公司的股东户数为60539户
常山药业:公司目前没有GLP-1双靶点及三靶点管线
证券之星 · 10-21
常山药业:公司目前没有GLP-1双靶点及三靶点管线
常山药业(300255)10月19日主力资金净卖出8213.31万元
证券之星 · 10-20
常山药业(300255)10月19日主力资金净卖出8213.31万元
常山药业最新公告:依诺肝素钠注射液通过欧盟DCP程序审评
证券之星 · 10-19
常山药业最新公告:依诺肝素钠注射液通过欧盟DCP程序审评
股市必读:常山药业新发布《关于依诺肝素钠注射液获得蒙古国药品注册证书的公告》
证券之星 · 10-19
股市必读:常山药业新发布《关于依诺肝素钠注射液获得蒙古国药品注册证书的公告》
常山药业最新公告:依诺肝素钠注射液获蒙古国药品注册证书
证券之星 · 10-16
常山药业最新公告:依诺肝素钠注射液获蒙古国药品注册证书
股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》
证券之星 · 10-15
股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》
常山药业(300255)披露控股股东部分股份解除质押公告,10月13日股价下跌1.59%
证券之星 · 10-13
常山药业(300255)披露控股股东部分股份解除质押公告,10月13日股价下跌1.59%
常山药业:全力推进艾本那肽上市许可审评工作
证券之星 · 10-12
常山药业:全力推进艾本那肽上市许可审评工作
常山药业:截至2026年10月9日,公司的股东户数为59957户
证券之星 · 10-12
常山药业:截至2026年10月9日,公司的股东户数为59957户
股市必读:常山药业新发布《关于控股股东部分股份质押的公告》
证券之星 · 10-12
股市必读:常山药业新发布《关于控股股东部分股份质押的公告》
常山药业(300255)10月8日主力资金净卖出1187.40万元
证券之星 · 10-09
常山药业(300255)10月8日主力资金净卖出1187.40万元
股市必读:常山药业新发布《关于控股股东部分股份质押的公告》
证券之星 · 10-09
股市必读:常山药业新发布《关于控股股东部分股份质押的公告》
常山药业(300255)股东高树华质押1350万股,占总股本1.47%
证券之星 · 10-08
常山药业(300255)股东高树华质押1350万股,占总股本1.47%
常山药业(300255)9月30日主力资金净卖出3084.86万元
证券之星 · 10-08
常山药业(300255)9月30日主力资金净卖出3084.86万元
常山药业(300255)9月29日主力资金净卖出1957.14万元
证券之星 · 09-30
常山药业(300255)9月29日主力资金净卖出1957.14万元
常山药业:公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料
证券之星 · 09-24
常山药业:公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料
公司概况
公司名称:
河北常山生化药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-08-19
主营业务:
河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是肝素钠、肝素钙、低分子量肝素钠(依诺肝素钠、达肝素钠)、低分子量肝素钙(那屈肝素钙)、透明质酸钠、枸橼酸西地那非、肝素钠注射液、低分子量肝素钙注射液、那屈肝素钙注射液、依诺肝素钠注射液、达肝素钠注射液。公司被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等。
发行价格:
28.00
{"stockData":{"symbol":"300255","market":"SZ","secType":"STK","nameCN":"常山药业","latestPrice":19.06,"timestamp":1793257419000,"preClose":19.33,"halted":0,"volume":16345899,"delay":0,"changeRate":-0.014,"floatShares":918000000,"shares":919000000,"eps":-0.3819,"marketStatus":"已收盘","change":-0.27,"latestTime":"10-29 15:00:00","open":19.25,"high":19.68,"low":19.04,"amount":316000000,"amplitude":0.0331,"askPrice":19.07,"askSize":53,"bidPrice":19.06,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-0.3819,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793323800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.33,"symbolType":"stock","openAndCloseTimeList":[[1793237400000,1793244600000],[1793250000000,1793257200000]],"highLimit":21.26,"lowLimit":17.4,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":919060878,"isCdr":false,"pbRate":14.96,"roa":"--","roe":"--","epsLYR":-0.39,"committee":0.409326,"marketValue":17517000000,"turnoverRate":0.0178,"status":1,"floatMarketCap":17491000000},"requestUrl":"/m/hq/s/300255/wiki","defaultTab":"wiki","newsList":[{"id":"2679477356","title":"图解常山药业三季报:第三季度单季净利润同比下降34.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679477356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679477356?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:33","pubTimestamp":1793270016,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业2026年三季报显示,前三季度公司主营收入7.36亿元,同比上升8.1%;归母净利润-3789.44万元,同比上升15.45%;扣非净利润-4260.15万元,同比上升10.66%;其中2026年第三季度,公司单季度主营收入2.61亿元,同比上升37.41%;单季度归母净利润-2113.26万元,同比下降34.36%;单季度扣非净利润-2074.04万元,同比下降19.01%;负债率73.88%,财务费用8303.89万元,毛利率22.47%。财报数据概要请见下图:本文数据来源于常山药业2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900043859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679471612","title":"常山药业(300255.SZ)发布前三季度业绩,归母净亏损3789.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679471612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679471612?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:56","pubTimestamp":1793267815,"startTime":"0","endTime":"0","summary":"智通财经APP讯,常山药业(300255.SZ)发布2026年三季度报告,前三季度,公司实现营业收入7.36亿元,同比增长8.10%。归属于上市公司股东净亏损3789.44万元。归属于上市公司股东的扣除非经常性损益净亏损4260.15万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0172","BK0070","BK0239","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677626874","title":"常山药业:公司已按要求提交补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2677626874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677626874?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:51","pubTimestamp":1792569066,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业10月21日在投资者关系平台上答复投资者关心的问题。请问:1、本次提交的补充资料,CDE 是否已经完成签收核验,审评是否已经重新启动?公司已按要求提交补充资料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100023732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300255","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677626808","title":"常山药业:截至2026年10月20日,公司的股东户数为60539户","url":"https://stock-news.laohu8.com/highlight/detail?id=2677626808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677626808?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:48","pubTimestamp":1792568893,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,请告知贵公司10月20日的股东人数是多少,谢谢!常山药业回复:尊敬的投资者,您好!截至2026年10月20日,公司的股东户数为60539户。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100023396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0070","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677462638","title":"常山药业:公司目前没有GLP-1双靶点及三靶点管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2677462638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677462638?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:48","pubTimestamp":1792568889,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,贵公司目前有没有glp-1双靶点及三靶点管线?常山药业回复:尊敬的投资者,您好!公司目前没有GLP-1双靶点及三靶点管线。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100023383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676630791","title":"常山药业(300255)10月19日主力资金净卖出8213.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676630791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676630791?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:18","pubTimestamp":1792459084,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月19日收盘,常山药业报收于19.24元,下跌3.22%,换手率2.94%,成交量27.02万手,成交额5.14亿元。近5日资金流向一览见下表:常山药业融资融券信息显示,融资方面,当日融资买入2336.59万元,融资偿还7093.6万元,融资净偿还4757.02万元。常山药业主营业务:拥有完整肝素产品产业链、能够同时从事肝素粗品、肝素原料药和肝素制剂药品研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000006472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676250911","title":"常山药业最新公告:依诺肝素钠注射液通过欧盟DCP程序审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2676250911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676250911?lang=zh_cn&edition=full","pubTime":"2026-10-19 16:36","pubTimestamp":1792399013,"startTime":"0","endTime":"0","summary":"常山药业(300255.SZ)公告称,公司近日收到欧盟克罗地亚药品及医疗器械管理局分散审批程序结束的通知,依诺肝素钠注射液已通过审评,结论为可批准。该药品用于预防静脉血栓栓塞性疾病、治疗深静脉栓塞等。本次通过审评是公司国际化注册的重要阶段性进展,若后续取得各成员国上市许可,将有利于拓展海外市场。目前公司肝素制剂产品海外销售收入占营收比例较低,预计不会对近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900020617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FESXmain","BK0070","300255","BK0239","FSXEmain","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676780305","title":"股市必读:常山药业新发布《关于依诺肝素钠注射液获得蒙古国药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676780305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676780305?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:22","pubTimestamp":1792347731,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘,常山药业报收于19.88元,下跌2.02%,换手率2.29%,成交量21.02万手,成交额4.31亿元。公司公告汇总:常山药业依诺肝素钠注射液获蒙古国药品注册证书,注册号FR20260911BP09272,有效期至2031年9月11日。公司公告汇总关于依诺肝素钠注射液获得蒙古国药品注册证书的公告河北常山生化药业股份有限公司近日收到通知,其药品依诺肝素钠注射液获得蒙古国药品监督管理部门签发的药品注册证书,注册号为FR20260911BP09272,规格为60mg/0.6ml;N2,有效期至2031年9月11日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0239","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675560995","title":"常山药业最新公告:依诺肝素钠注射液获蒙古国药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2675560995","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675560995?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:10","pubTimestamp":1792141829,"startTime":"0","endTime":"0","summary":"常山药业(300255.SZ)公告称,公司药品依诺肝素钠注射液获得蒙古国药品监督管理部门签发的药品注册证书,注册证有效期至2031年9月11日。该药品用于预防静脉血栓栓塞性疾病、治疗深静脉栓塞等。本次获注册证书对公司拓展海外市场带来积极影响,但肝素制剂产品海外销售收入占公司营收比例较低,出口销售受海外市场政策、汇率等因素影响,存在不确定性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600028818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0239","BK0070","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675321347","title":"股市必读:常山药业新发布《关于控股股东部分股份解除质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675321347","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675321347?lang=zh_cn&edition=full","pubTime":"2026-10-15 02:10","pubTimestamp":1792001425,"startTime":"0","endTime":"0","summary":"截至2026年10月14日收盘,常山药业报收于20.88元,下跌0.81%,换手率1.38%,成交量12.66万手,成交额2.65亿元。当日关注点交易信息汇总:10月14日常山药业主力资金净流出451.23万元,占总成交额1.7%。公司公告汇总:控股股东高树华先生600万股股份于10月12日解除质押,占公司总股本0.65%。截至公告披露日,高树华先生累计质押股份193,206,400股,占其所持股份比例68.84%,占公司总股本比例21.02%。高树华先生目前持股280,644,728股,持股比例30.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0172","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675368818","title":"常山药业(300255)披露控股股东部分股份解除质押公告,10月13日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675368818","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675368818?lang=zh_cn&edition=full","pubTime":"2026-10-13 22:23","pubTimestamp":1791901418,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘,常山药业报收于21.05元,较前一交易日下跌1.59%,最新总市值为193.46亿元。近日,河北常山生化药业股份有限公司发布公告称,公司控股股东高树华先生所持有的6,000,000股公司股份已于2026年10月12日解除质押,占其所持股份比例2.14%,占公司总股本比例0.65%。本次解除质押的股份此前质押给****银行股份有限公司正定支行,起始日为2025年9月29日。高树华先生目前持股280,644,728股,持股比例30.54%。公司表示其质押风险总体可控,不存在平仓风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300039828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0172","300255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674822410","title":"常山药业:全力推进艾本那肽上市许可审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2674822410","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674822410?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:27","pubTimestamp":1791790039,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问:你好董秘董高管,公司在业绩说明会上说公司有信心将阿贝上市,这是真的吗 我看每次董秘回复都是消极信号释放的不确定因素,会不会前后矛盾!常山药业回复:尊敬的投资者,您好。业绩说明会上的相关表述,指公司管理层积极配合CDE的审评要求,全力推进艾本那肽(阿贝那肽)的上市许可审评工作。但创新药审评受多重因素影响,最终审评结果及审评完成时间均存在不确定性。请投资者高度关注上述风险,谨慎投资。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200014676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0172","BK0070","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674113822","title":"常山药业:截至2026年10月9日,公司的股东户数为59957户","url":"https://stock-news.laohu8.com/highlight/detail?id=2674113822","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674113822?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:27","pubTimestamp":1791790039,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,请问截至9月30日的股东人数是多少?常山药业回复:尊敬的投资者,您好!截至2026年9月30日的股东人数,公司将在定期报告中披露,请您留意公司后续发布的定期报告。截至2026年10月9日,公司的股东户数为59957户。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200014678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300255","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674384348","title":"股市必读:常山药业新发布《关于控股股东部分股份质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674384348","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674384348?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:17","pubTimestamp":1791739027,"startTime":"0","endTime":"0","summary":"公司公告汇总关于控股股东部分股份质押的公告河北常山生化药业股份有限公司控股股东高树华将其持有的13,500,000股股份质押给****银行股份有限公司正定支行,占其所持股份4.81%,占公司总股本1.47%,质押用途为无偿为公司借款提供担保。本次质押后,高树华累计质押股份199,206,400股,占其所持股份70.98%,占公司总股本21.67%。未来半年内到期质押股份2300.00万股,对应融资余额12,900.00万元,还款资金来源为后续股票质押融资等方式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0172","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674881272","title":"常山药业(300255)10月8日主力资金净卖出1187.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674881272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674881272?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:18","pubTimestamp":1791508718,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月8日收盘,常山药业报收于21.89元,下跌4.58%,换手率2.49%,成交量22.84万手,成交额5.09亿元。近5日资金流向一览见下表:常山药业融资融券信息显示,融资方面,当日融资买入2109.55万元,融资偿还3201.31万元,融资净偿还1091.76万元。常山药业主营业务:拥有完整肝素产品产业链、能够同时从事肝素粗品、肝素原料药和肝素制剂药品研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900007333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0070","BK0239","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674001426","title":"股市必读:常山药业新发布《关于控股股东部分股份质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674001426","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674001426?lang=zh_cn&edition=full","pubTime":"2026-10-09 01:17","pubTimestamp":1791479829,"startTime":"0","endTime":"0","summary":"公司公告汇总关于控股股东部分股份质押的公告河北常山生化药业股份有限公司控股股东高树华将其持有的13,500,000股股份质押给****银行股份有限公司正定支行,占其所持股份比例4.81%,占公司总股本比例1.47%,质押用途为无偿为公司借款提供担保。本次质押后,高树华累计质押股份199,206,400股,占其所持股份比例70.98%,占公司总股本比例21.67%。高树华所持股份不存在限售、冻结情形,亦不涉及业绩补偿义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900001571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0172","300255","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673076545","title":"常山药业(300255)股东高树华质押1350万股,占总股本1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673076545","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673076545?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:30","pubTimestamp":1791455449,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业10月8日公开信息显示,股东高树华向****银行股份有限公司正定支行合计质押1350.0万股,占总股本1.47%。质押详情见下表:截止本公告日,股东高树华已累计质押股份1.99亿股,占其持股总数的70.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800026989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673035049","title":"常山药业(300255)9月30日主力资金净卖出3084.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673035049?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:05","pubTimestamp":1791421523,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月30日收盘,常山药业报收于22.94元,上涨3.71%,换手率2.77%,成交量25.46万手,成交额5.84亿元。近5日资金流向一览见下表:常山药业融资融券信息显示,融资方面,当日融资买入3051.37万元,融资偿还4128.66万元,融资净偿还1077.3万元。常山药业主营业务:拥有完整肝素产品产业链、能够同时从事肝素粗品、肝素原料药和肝素制剂药品研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300255","BK0172"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226054","title":"常山药业(300255)9月29日主力资金净卖出1957.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671226054?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:17","pubTimestamp":1790731046,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月29日收盘,常山药业报收于22.12元,下跌1.51%,换手率1.94%,成交量17.82万手,成交额4.0亿元。近5日资金流向一览见下表:常山药业融资融券信息显示,融资方面,当日融资买入1988.2万元,融资偿还3249.74万元,融资净偿还1261.54万元。常山药业主营业务:拥有完整肝素产品产业链、能够同时从事肝素粗品、肝素原料药和肝素制剂药品研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000007824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0172","300255","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669043745","title":"常山药业:公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2669043745","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669043745?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:42","pubTimestamp":1790210536,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业(300255)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,请问公司收到阿贝那肽二次发布的具体时间?资料提交的具体截止时间是9月30日吗?常山药业回复:尊敬的投资者,您好。公司已于近日提交了艾本那肽(阿贝那肽)上市审评的补充资料。艾本那肽上市审评后续流程环节仍然较多、审评周期较长,最终审评结果及完成审评时间均存在不确定性。请投资者高度关注上述风险,慎重决策。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400008078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300255","BK0239","BK0070","BK0172"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793271896143,"stockEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.1394},{"period":"3month","weight":-0.1983},{"period":"6month","weight":-0.5326},{"period":"1year","weight":-0.6651},{"period":"ytd","weight":-0.6887}],"compareEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.0372},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.1047},{"period":"1year","weight":-0.0769},{"period":"ytd","weight":-0.0724}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"河北常山生化药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"60539人(较上一季度增加0.97%)","perCapita":"15158股","listingDate":"2011-08-19","address":"河北省石家庄市正定县中国(河北)自由贸易试验区正定片区高新技术产业开发区南区梦龙街71号","registeredCapital":"91906万元","survey":" 河北常山生化药业股份有限公司的主营业务是肝素系列产品的研发、生产和销售。公司的主要产品是肝素钠、肝素钙、低分子量肝素钠(依诺肝素钠、达肝素钠)、低分子量肝素钙(那屈肝素钙)、透明质酸钠、枸橼酸西地那非、肝素钠注射液、低分子量肝素钙注射液、那屈肝素钙注射液、依诺肝素钠注射液、达肝素钠注射液。公司被认定为国家企业技术中心、中国创业创新典型示范企业、河北省A级研发中心、国家级高新技术企业、国家地方工程实验室、河北省多糖类药物工程技术研究中心、河北省出口名牌等。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"常山药业,300255,常山药业股票,常山药业股票老虎,常山药业股票老虎国际,常山药业行情,常山药业股票行情,常山药业股价,常山药业股市,常山药业股票价格,常山药业股票交易,常山药业股票购买,常山药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"常山药业(300255)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供常山药业(300255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}